otic – Scalper1

Otonomy Drug Miss, BlackBerry Buyback Lead After Hours Movers

Drug stocks Otonomy (OTIC) and PTC Therapeutics (PTCT) led after-hours movers Thursday, as did teen clothing retailer Aeropostale (ARO) and ailing smartphone maker BlackBerry (BBRY). Otonomy, a clinical-stage biopharmaceutical company that specializes in ear drugs, said that its phase two-B OTO-104 drug trial “narrowly missed” its primary endpoint of reducing Meniere’s disease — a chronic condition that the company says is characterized by acute

IPO Calendar: Summer Slowdown Begins With Just 4 IPOs

Following the usual summer slowdown, just four IPOs are scheduled for the week of Aug. 11, including two biotechs. The largest initial public offering planned is Otonomy (OTIC), a clinical stage developer of treatments for ear diseases. It plans to raise $80 million by offering 5.3 million shares at a price range of 14 to 16. Another is Zosano (ZSAN), an early stage biotech developing transdermal patches to treat osteoporosis, with an IPO that was